Cipla Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CIPLA, and when can generic versions of CIPLA drugs launch?
CIPLA has ninety-one approved drugs.
There are six US patents protecting CIPLA drugs. There are thirty-three tentative approvals on CIPLA drugs.
There are thirty patent family members on CIPLA drugs in twenty-one countries and four hundred and thirty-nine supplementary protection certificates in seventeen countries.
Summary for Cipla
| International Patents: | 30 |
| US Patents: | 6 |
| Tradenames: | 80 |
| Ingredients: | 80 |
| NDAs: | 91 |
| Patent Litigation for Cipla: | See patent lawsuits for Cipla |
| PTAB Cases with Cipla as petitioner: | See PTAB cases with Cipla as petitioner |
Drugs and US Patents for Cipla
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cipla Usa | ZEMDRI | plazomicin sulfate | SOLUTION;INTRAVENOUS | 210303-001 | Jun 25, 2018 | RX | Yes | Yes | 8,383,596 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Cipla | ATAZANAVIR SULFATE | atazanavir sulfate | CAPSULE;ORAL | 200626-002 | Aug 9, 2018 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Cipla | PREGABALIN | pregabalin | CAPSULE;ORAL | 212280-003 | Jan 10, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Cipla Drugs
Supplementary Protection Certificates for Cipla Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2666774 | CR 2020 00037 | Denmark | ⤷ Sign Up | PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF THE MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF THE SODIUM SALT; REG. NO/DATE: EU/1/19/1420 20200217 |
| 2101777 | 93081 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: AMBRISENTAN UTILISE EN TRAITEMENT COMBINE AVEC TADALAFIL; FRIST REGISTRATION: 20151125 |
| 2666774 | LUC00167 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: RELEBACTAM, EVENTUELLEMENT SOUS FORME DE MONOHYDRATE, IMIPENEME ET CILASTATINE, EVENTUELLEMENT SOUS FORME DE SEL DE SODIUM; AUTHORISATION NUMBER AND DATE: EU/1/19/1420 20200217 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
